Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has inked a comarketing agreement focused on computational genetic analysis and trait optimization for cannabis and psychedelics. The agreement was signed through Delic Labs, which inked the deal with GTR Research Inc. (“GTR”). GTR is leading out in applying cutting-edge computational and biotech to cannabis and psychedelics. According to the company, Delic Labs will provide genetic analysis of psychedelic mushrooms and cannabis to producers in Canada; the analysis will include sample preparation, DNA extraction, whole-genome sequencing, computational analysis and reporting, as well as detailed information regarding specific areas of the genome relating to traits of highest commercial interest. A federally authorized psilocybin and cannabis research laboratory, Delic Labs specializes in extraction, analytical testing and chemical process development. The facility is one of only a handful of licensed psilocybin research labs in Canada with clients that include some of the largest brands in the world. “Partnering with GTR will give us the most comprehensive genomic insights in the industry and build on our efforts to provide the highest standards and quality control for psychedelic and cannabis compounds,” said Delic Labs cofounder Dr. Markus Roggen in the press release. “As demand continues to grow for healthier, more effective alternatives to traditional medicines, our combined knowledge will offer producers new, best-in-class products to serve their markets.”
To view the full press release, visit https://ibn.fm/aC9sk
About Delic Corp Inc.
Delic is the leading psychedelic wellness platform, committed to addressing the mental health crisis by increasing access to science-backed benefits for all and reframing the psychedelic conversation. The company owns and operates an umbrella of related businesses, including as Reality Sandwich and Delic Radio, trusted media and e-commerce platforms; Delic Labs, the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology; Meet Delic, the premiere psychedelic wellness event; and the largest chain of psychedelic wellness clinics in the country, with Ketamine Infusion Centers and Ketamine Wellness Centers (pending acquisition). Delic is backed by a team of industry and cannabis veterans and a diverse network, whose mission is to provide education, research, high-quality products and treatment options to the masses. For more information about the company, visit www.DelicCorp.com.
NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.